Use of hormones in doping and cancer risk

Ann Ig. 2019 Nov-Dec;31(6):590-594. doi: 10.7416/ai.2019.2319.

Abstract

Hormones with anabolic properties such as growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are commonly abused among professional and recreational athletes to enhance physical ability. Despite their adverse effects are well-documented, the use of GH and IGF-1 has recently grown. This article highlights the anabolic activity related to mechanisms of cancer development and progression. GH/IGF-1 axis is able to activate cellular mechanisms that modulate every key stage of cancer formation and progression, such as inhibition of apoptosis, resistance to treatments, and induction of angiogenesis, metastatic process and cell proliferation. Results from pre-clinical studies and epidemiological observations in patients with an excess of GH and IGF-1 production or treated with these hormones showed a positive association with the risk to develop several types of cancer. In conclusion, athletes should be made aware that long-term treatment with doping agents might increase the risk of developing cancer, especially if associated with other licit or illicit drugs and/or high-protein diet.

Keywords: Cancer; Doping; Growth hormone; IGF-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Athletes
  • Disease Progression
  • Doping in Sports*
  • Human Growth Hormone / administration & dosage
  • Human Growth Hormone / adverse effects*
  • Humans
  • Insulin-Like Growth Factor I / administration & dosage
  • Insulin-Like Growth Factor I / adverse effects*
  • Neoplasms / chemically induced*
  • Neoplasms / epidemiology
  • Neoplasms / pathology
  • Risk
  • Substance-Related Disorders / complications
  • Substance-Related Disorders / epidemiology

Substances

  • IGF1 protein, human
  • Human Growth Hormone
  • Insulin-Like Growth Factor I